Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Multicenter, Phase 2 Study of Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) Alone or in Combination With Lomustine in Recurrent WHO Grade IV Malignant Glioma Patients

Trial Profile

A Randomized, Multicenter, Phase 2 Study of Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) Alone or in Combination With Lomustine in Recurrent WHO Grade IV Malignant Glioma Patients

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Jan 2019

At a glance

  • Drugs Recombinant polio virus vaccine Istari Oncology (Primary) ; Lomustine
  • Indications Glioma
  • Focus Therapeutic Use
  • Sponsors Istari Oncology
  • Most Recent Events

    • 10 Jan 2019 Planned number of patients changed from 62 to 102.
    • 05 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top